心痛舒方防治冠心病PCI术后再狭窄的临床研究

Clinical Observation on Xintongshu Formula in Preventing and Treating Restenosis Post PCI in Patients with Coronary Heart Disease

目的观察心痛舒方对冠心病病人PCI术后再狭窄及不良心血管事件发生的干预作用。方法选择2015年5月—2016年10月在我院住院行PCI术的冠心病病人100例,随机分为两组。对照组(常规治疗组)50例和治疗组(常规治疗+心痛舒方)50例,治疗组在对照组基础上加服心痛舒方(中药制剂),每天1次,每次100mL,连续服药3个月,两组病人随访6个月,观察术后不良心血管事件发生率及支架内再狭发生率。结果术后随访6个月,再发心绞痛8例,其中治疗组2例(4%),对照组6例(12%),对照组发生非致死性急性心肌梗死1例(2%),上述9例病人均再次PCI治疗。两组均未发生心源性死亡病例。两组相比较,在发生急性心肌梗死和心源性死亡方面差异无统计学意义(P>0.05)。治疗组心绞痛、再次血运重建、联合心血管事件发生率较对照组低(P<0.05)。两组介入前后冠脉血管狭窄程度、最小管腔直径、管腔早期获得差异均无统计学意义(P>0.05);6个月复查造影:病变血管管腔直径对照组较治疗组明显增加(P<0.05),再狭窄发生率治疗组较对照组低(6%vs 18%,P<0.05)。结论心痛舒方对冠心病病人PCI术后再狭窄的预防有一定作用。

Objective To observe the clinical efficacy of Xintongshu prescription（XTSP）in preventing and treating the restenosis after percutaneous coronary intervention（PCI）in patients with coronary heart disease（CHD）.Methods One hundred patients with CHD undergoing PCI from May 2015 to October 2016 were randomly divided into two groups：control group（n =50）treated with routine treatment,and treatment group（n =50）treated with routine treatment and XTSP for 3 months.The patients were followed up for 6 months.The incidences of adverse cardiovascular events and coronary restenosis were observed.Results The incidence of the adverse cardiovascular events in treatment group was lower than that in control group（P 〈0.05）.The incidence of coronary restenosis in treatment group was lower than that in control group（6% vs 18%,P 〈0.05）.Conclusion XTSP can effectively prevent coronary restenosis after PCI in patients with CAD.